$MLND News

Last published 5y ago

5y agoMLNDTempest and Millendo Announce Stockholder Approval of MergerGlobeNewswireSOUTH SAN FRANCISCO, Calif. and ANN ARBOR, Mich., June 22, 2021 (GLOBE NEWSWIRE) -- Tempest Therapeutics, Inc. ("Tempest"), a clinical-stage oncology company developing potentially first-in-class therapeutics that combine both targeted and immune-media
5y agoLEAF MLND LATN GNLNMoore Kuehn Encourages LEAF, MLND, LATN, and GNLN Investors to Contact Law FirmPR NewswireMoore Kuehn, PLLC, a law firm focusing in securities litigation located on Wall Street in downtown New York City, is investigating potential claims...
5y agoMLNDTempest and Millendo Announce Proposed Merger AgreementBusiness WireSOUTH SAN FRANCISCO, Calif. & ANN ARBOR, Mich.--(BUSINESS WIRE)--Tempest Therapeutics, Inc. (“Tempest”), a privately-held clinical-stage oncology company developing potentially first-in-class therapeutics that combine both targeted and immune-mediated mechanisms, and Millendo Therapeutics, Inc. (Nasdaq: MLND) (“Millendo”), announced today that they have entered into a definitive agreement under wh ...
5y agoMLNDMillendo Therapeutics Provides Pipeline and Business UpdateBusiness WireANN ARBOR, Mich.--(BUSINESS WIRE)--Millendo Therapeutics, Inc. (Nasdaq: MLND), announced today that its Board of Directors has decided to discontinue further investment in MLE-301, a selective neurokinin 3 receptor (NK3R) antagonist for the treatment of menopausal vasomotor symptoms (VMS), based on an analysis of the pharmacokinetic and pharmacodynamic data from the ongoing single ascending dose p ...
6y agoMLNDMillendo Therapeutics Reports Third Quarter 2020 Operating and Financial ResultsBusiness WireANN ARBOR, Mich.--(BUSINESS WIRE)--Millendo Therapeutics, Inc. (Nasdaq: MLND), a clinical-stage biopharmaceutical company primarily focused on developing novel treatments for endocrine diseases with significant unmet needs, today provided a corporate update and reported financial results for the quarter ended September 30, 2020.
6y agoMLNDMillendo Therapeutics Announces Initiation of First-in-Human Clinical Trial of MLE-301, a Selective NK3R AntagonistBusiness WireANN ARBOR, Mich.--(BUSINESS WIRE)--Millendo Therapeutics, Inc. (Nasdaq: MLND), a clinical-stage biopharmaceutical company primarily focused on developing novel treatments for endocrine diseases with significant unmet needs, announced dosing of the first subject in a Phase 1 clinical trial evaluating the safety, pharmacokinetics and preliminary efficacy of MLE-301, a selective neurokinin 3 receptor ...
6y agoMLNDMillendo Therapeutics to Participate in September Investor ConferencesBusiness WireANN ARBOR, Mich.--(BUSINESS WIRE)--Millendo Therapeutics, Inc. (Nasdaq: MLND), a clinical-stage biopharmaceutical company primarily focused on developing novel treatments for endocrine diseases with significant unmet needs, today announced that management will participate in the following virtual healthcare investor conferences:
6y agoMLNDMillendo Therapeutics Reports Second Quarter 2020 Operating and Financial ResultsBusiness WireANN ARBOR, Mich.--(BUSINESS WIRE)--Millendo Therapeutics, Inc. (Nasdaq: MLND), a clinical-stage biopharmaceutical company primarily focused on developing novel treatments for endocrine diseases with significant unmet needs, today provided a corporate update and reported financial results for the quarter ended June 30, 2020.
6y agoMLNDMillendo Therapeutics to Present at the 2020 Wedbush PacGrow Healthcare Virtual ConferenceBusiness WireANN ARBOR, Mich.--(BUSINESS WIRE)--Millendo Therapeutics, Inc. (Nasdaq: MLND), a clinical stage biopharmaceutical company primarily focused on developing novel treatments for endocrine diseases with significant unmet needs, announced today that Julia C. Owens, Ph.D., President and Chief Executive Officer, will present at the 2020 Wedbush PacGrow Healthcare Virtual Conference on Wednesday, August 1 ...
6y agoMLNDMillendo Therapeutics Provides Corporate and Pipeline UpdateBusiness WireANN ARBOR, Mich.--(BUSINESS WIRE)--Millendo Therapeutics, Inc. (Nasdaq: MLND), a biopharmaceutical company primarily focused on developing novel treatments for endocrine diseases with significant unmet needs, announced today that it has taken steps forward in its evaluation of strategic options to determine the company’s future direction. As part of these efforts, Millendo has engaged SVB Leerink ...
6y agoMLNDMillendo Therapeutics Reports First Quarter 2020 Operating and Financial ResultsBusiness WireANN ARBOR, Mich.--(BUSINESS WIRE)--Millendo Therapeutics, Inc. (Nasdaq:MLND), a clinical stage biopharmaceutical company primarily focused on developing novel treatments for endocrine diseases with significant unmet needs, today provided a corporate update and reported financial results for the quarter ended March 31, 2020.
6y agoMLNDMillendo Therapeutics Announces Topline Results for Pivotal Phase 2b Study of Livoletide in Patients with Prader-Willi Syndrome (PWS)Business WireANN ARBOR, Mich.--(BUSINESS WIRE)--Millendo Therapeutics, Inc. (Nasdaq: MLND), a biopharmaceutical company primarily focused on developing novel treatments for endocrine diseases, announced today that it is discontinuing the development of livoletide as a potential treatment for Prader-Willi syndrome (PWS). The decision to discontinue the PWS program was based on topline data from the pivotal Phas ...
6y agoMLNDMillendo Therapeutics Reports Full Year 2019 Operating and Financial ResultsBusiness WireANN ARBOR, Mich.--(BUSINESS WIRE)--Millendo Therapeutics, Inc. (Nasdaq: MLND), a late-stage biopharmaceutical company primarily focused on developing novel treatments for orphan endocrine diseases, today provided a corporate update and reported financial results for the year ended December 31, 2019.
6y agoMLNDMillendo Therapeutics to Present at Upcoming Investor ConferencesBusiness WireANN ARBOR, Mich.--(BUSINESS WIRE)--Millendo Therapeutics, Inc. (Nasdaq: MLND), a late-stage biopharmaceutical company primarily focused on developing novel treatments for orphan endocrine diseases, announced today that Julia C. Owens, Ph.D., President and Chief Executive Officer, and company management will participate in the following healthcare investor conferences:
6y agoMLNDMillendo Therapeutics to Present at the 9th Annual SVB Leerink Global Healthcare ConferenceBusiness WireANN ARBOR, Mich.--(BUSINESS WIRE)--Millendo Therapeutics, Inc. (Nasdaq: MLND), a late-stage biopharmaceutical company primarily focused on developing novel treatments for orphan endocrine diseases, announced today that Julia C. Owens, Ph.D., President and Chief Executive Officer, will present at the 9th Annual SVB Leerink Global Healthcare Conference in New York City on Wednesday, February 26, 202 ...
6y agoMLNDMillendo Therapeutics Appoints Christophe Arbet-Engels, MD, PhD, as Chief Medical OfficerBusiness WireANN ARBOR, Mich.--(BUSINESS WIRE)--Millendo Therapeutics, Inc. (Nasdaq: MLND), a late-stage biopharmaceutical company primarily focused on developing novel treatments for orphan endocrine diseases, announced today that Christophe Arbet-Engels, MD, PhD, has joined the company as Chief Medical Officer. The company also announced that it expects to report topline results from the Phase 2b portion of ...
6y agoMLNDMillendo Therapeutics Promotes Thomas Hoover to Chief Commercial OfficerBusiness WireANN ARBOR, Mich.--(BUSINESS WIRE)--Millendo Therapeutics, Inc. (Nasdaq: MLND), a clinical-stage biopharmaceutical company primarily focused on developing novel treatments for orphan endocrine diseases with significant unmet needs, today announced the promotion of Thomas Hoover to the newly created position of Chief Commercial Officer. Mr. Hoover joined Millendo in 2016 and has served as the compan ...
6y agoMLNDGeoff Nichol Appointed to Millendo Therapeutics Board of DirectorsBusiness WireANN ARBOR, Mich.--(BUSINESS WIRE)--Millendo Therapeutics, Inc. (Nasdaq: MLND), a clinical-stage biopharmaceutical company primarily focused on developing novel treatments for orphan endocrine diseases with significant unmet needs, today announced that Geoff Nichol, M.B., Ch.B., M.B.A., has been appointed to the Board of Directors. Dr. Nichol currently serves as Chief Medical Officer at BioMarin wh ...
6y agoMLNDMillendo Therapeutics Announces Pricing of Public Offering of Common StockBusiness WireANN ARBOR, Mich.--(BUSINESS WIRE)--Millendo Therapeutics, Inc. (Nasdaq: MLND), a late-stage biopharmaceutical company developing novel treatments primarily for orphan endocrine diseases, today announced the pricing of its underwritten public offering of 4,166,667 shares of its common stock at a public offering price of $6.00 per share, for aggregate gross proceeds of $25.0 million, before deductin ...
6y agoMLNDMillendo Therapeutics Announces Proposed Public Offering of Common StockBusiness WireANN ARBOR, Mich.--(BUSINESS WIRE)--Millendo Therapeutics, Inc. (Nasdaq: MLND), a late-stage biopharmaceutical company developing novel treatments primarily for orphan endocrine diseases, today announced that it has commenced an underwritten public offering of shares of its common stock. Millendo also intends to grant the underwriters a 30-day option to purchase up to an additional 15% of the share ...
7y agoMLNDMillendo Therapeutics Reports Third Quarter 2019 Operating and Financial ResultsBusiness WireANN ARBOR, Mich.--(BUSINESS WIRE)--Millendo Therapeutics, Inc. (Nasdaq: MLND), a clinical-stage biopharmaceutical company primarily focused on developing novel treatments for orphan endocrine diseases with significant unmet needs, today provided a corporate update and reported financial results for the quarter ended September 30, 2019.
7y agoMLNDMillendo Therapeutics Completes Patient Recruitment for Pivotal Study of Livoletide in Prader-Willi SyndromeBusiness WireANN ARBOR, Mich.--(BUSINESS WIRE)--Millendo Therapeutics, Inc. (Nasdaq: MLND), a clinical-stage biopharmaceutical company developing novel treatments primarily for orphan endocrine diseases, today announced that the Phase 2b portion of its pivotal Phase 2b/3 clinical study of livoletide in patients with Prader-Willi syndrome (PWS), called ZEPHYR, has completed recruitment for patients ages 8 to 65 ...
7y agoMLNDMillendo Therapeutics to Present at the Stifel 2019 Healthcare ConferenceBusiness WireANN ARBOR, Mich.--(BUSINESS WIRE)--Millendo Therapeutics, Inc. (Nasdaq: MLND), a clinical-stage biopharmaceutical company developing novel treatments primarily for orphan endocrine diseases, announced today that Julia C. Owens, Ph.D., President and Chief Executive Officer, will present at the Stifel 2019 Healthcare Conference in New York City on Tuesday, November 19, 2019 at 9:45 a.m. EST.
7y agoMLNDMillendo Therapeutics to Host Prader-Willi Syndrome (PWS) Breakfast Symposium on Thursday, November 14, 2019Business WireANN ARBOR, Mich.--(BUSINESS WIRE)--Millendo Therapeutics, Inc. (Nasdaq: MLND), a clinical-stage biopharmaceutical company developing novel treatments primarily for orphan endocrine diseases, announced today that it will host a PWS Breakfast Symposium on Thursday, November 14, 2019 from 8:30 a.m. to 10:30 a.m. EST. The event will feature a clinical and scientific presentation by Shawn E. McCandless ...
7y agoMLNDMillendo Therapeutics to Present at Prader-Willi Syndrome ConferencesBusiness WireANN ARBOR, Mich.--(BUSINESS WIRE)--Millendo Therapeutics, Inc. (Nasdaq: MLND), a clinical-stage biopharmaceutical company developing novel treatments primarily for orphan endocrine diseases, today announced that it will participate in oral presentations and poster sessions at two upcoming Prader-Willi syndrome (PWS) conferences. Presentations will be made by both PWS clinician thought leaders and ...
7y agoMLNDMillendo Therapeutics to Participate in September Investor ConferencesBusiness WireANN ARBOR, Mich.--(BUSINESS WIRE)--Millendo Therapeutics, Inc. (Nasdaq: MLND), a clinical-stage biopharmaceutical company developing novel treatments for orphan endocrine diseases, today announced that senior management will present company overviews and conduct one-on-one investor meetings at the following healthcare investor conferences:
7y agoMLNDMillendo Therapeutics Appoints Tamara Joseph as General Counsel and Ryan Zeidan as Chief Development OfficerBusiness WireANN ARBOR, Mich.--(BUSINESS WIRE)--Millendo Therapeutics, Inc. (Nasdaq: MLND), a clinical-stage biopharmaceutical company primarily focused on developing novel treatments for orphan endocrine diseases with significant unmet needs, announced today the appointments of Tamara Joseph, JD, LLM, as General Counsel and Corporate Secretary and Ryan Zeidan, PhD, as Chief Development Officer. Ms. Joseph suc ...
7y agoMLNDMillendo Therapeutics Reports Second Quarter 2019 Operating and Financial ResultsBusiness WireANN ARBOR, Mich.--(BUSINESS WIRE)--Millendo Therapeutics, Inc. (Nasdaq: MLND), a clinical-stage biopharmaceutical company primarily focused on developing novel treatments for orphan endocrine diseases with significant unmet needs, today provided a corporate update and reported financial results for the quarter ended June 30, 2019.
7y agoMLNDMillendo Therapeutics to Participate in August Investor ConferencesBusiness WireANN ARBOR, Mich.--(BUSINESS WIRE)--Millendo Therapeutics, Inc. (Nasdaq: MLND), a clinical-stage biopharmaceutical company developing novel treatments for orphan endocrine diseases, today announced that management will present company overviews and conduct one-on-one investor meetings at the following healthcare investor conferences:
7y agoMLNDMillendo Therapeutics Announces Departure of Chief Medical OfficerBusiness WireANN ARBOR, Mich.--(BUSINESS WIRE)--Millendo Therapeutics, Inc. (Nasdaq: MLND), a clinical-stage biopharmaceutical company developing novel treatments for orphan endocrine diseases, today announced that Pharis Mohideen, M.D., is departing the company to pursue a career opportunity closer to his home in New Jersey, allowing him to spend more time with his family.